Hedge Funds Are Crazy About Jounce Therapeutics, Inc. (JNCE)
In this article we will check out the progression of hedge fund sentiment towards Jounce Therapeutics, Inc. (NASDAQ:JNCE) and determine whether it is a good investment right now.
Jounce Therapeutics Inc. (JNCE)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Opaleye Management James A. Silverman | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.02 | 20,286 | Large Shareholder | 5,300,087 | 2023-03-14 | Filing | |
| $0.99 | 65,701 | Large Shareholder | 5,279,801 | 2023-03-13 | Filing | |
| $7.84 | 1,900 | Officer | 1,900 | 2018-06-15 | Filing | |
| $16.00 | 5,000 | Director | 5,000 | 2017-02-01 | Filing | |
| $16.00 | 6,700 | Director | 27,025 | 2017-02-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.85 | 39,228 | Director | 188,779 | 2023-04-04 | Filing | |
| $1.12 | 5,126 | Officer | 103,417 | 2023-01-10 | Filing | |
| $1.10 | 4,159 | Officer | 108,543 | 2023-01-09 | Filing | |
| $1.12 | 24,879 | Officer, Director | 228,007 | 2023-01-10 | Filing | |
| $1.10 | 20,191 | Officer, Director | 252,886 | 2023-01-09 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 0 | $0 | 0% | |
| 2. | 0 | $0 | 0% | |
| 3. | 0 | $0 | 0% | |
| 4. | 0 | $0 | 0% | |
| 5. | 0 | $0 | 0% |
News See All
Were Hedge Funds Right About Jounce Therapeutics, Inc. (JNCE)?
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors...
Is JNCE A Good Stock To Buy Now?
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns.
Should You Avoid Jounce Therapeutics, Inc. (JNCE)?
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies.
Did Hedge Funds Drop The Ball On Jounce Therapeutics, Inc. (JNCE)?
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November.
Is Jounce Therapeutics, Inc. (JNCE) A Good Stock To Buy?
After several tireless days we have finished crunching the numbers from nearly 750 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed...
Hedge Funds Are Crazy About Jounce Therapeutics, Inc. (JNCE)
We at Insider Monkey have gone over 700 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of September...
13G Filing: Partner Fund Management and Jounce Therapeutics Inc (JNCE)
PFM is the investment advisor for HEGM, HCM, HCOPP, HCLM and HCONC. PIM is the investment advisor for HCP. PFM-GP and PIM-GP are, respectively, the general partners of PFM and PIM. Grossman is...